Market Newsdesk

VENTURA, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Sysco Ventura announced today that Richard Edmonds, Driver, will represent Sysco at the International Foodservice Distributors Association (IFDA) National Championship in Orlando, Florida, October 12-14, 2023.

Richard emerged as a Top 16 finalist out of 2,200 other Sysco competitors based on his skills performance and safety record during his 18-year tenure at Sysco. As a finalist, Sysco also provides Richard with a prize package that includes a Walt Disney World^® family vacation.

Sysco Rodeo is an annual competition for the company’s industrial athletes to display their knowledge and skills in driving, selecting, and forklift operations. This year’s Rodeo had individual competitions taking place at 92 Sysco sites across the U.S. between May and August.

The top 12 delivery partners and the top four warehouse colleagues will now advance to Orlando, putting their skills to the test against other top industry drivers and warehouse colleagues from across the country.

“All of us at Sysco are so proud of Richard and all our driver and warehouse colleagues who participated in Sysco Rodeo this year,” said Daniel Purefoy, Sysco’s Senior Vice President, Chief Supply Chain Officer. “These events bring fun, food, and friendly competition for the participants and their families while highlighting the skill and talent that makes Sysco the best in the business. We look forward to bringing home some trophies from Orlando!”

About Sysco

Sysco is the global leader in selling, marketing and distributing food products to restaurants, healthcare and educational facilities, lodging establishments and other customers who prepare meals away from home. Its family of products also includes equipment and supplies for the foodservice and hospitality industries. With more than 72,000 colleagues, the company operates 334 distribution facilities worldwide and serves approximately 725,000 customer locations. For fiscal year 2023 that ended July 1, 2023, the company generated sales of more than $76 billion. Information about our Sustainability program, including Sysco’s 2022 Sustainability Report and 2022 Diversity, Equity & Inclusion Report, can be found at www.sysco.com.

Media Contact:

Shannon Mutschler
Sr. Director, External Communications
[email protected]

TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) — REE Automotive Ltd. (Nasdaq: REE), an automotive technology company and provider of full by-wire electric trucks and platforms, today announced that Carlton Rose has been appointed Chairman of its Board of Directors (Board), effective upon his re-election to the Board at REE’s 2023 Annual Meeting of Shareholders scheduled for October 16, 2023 (AGM). Rose joined REE’s Board in June shortly after retiring from a long and distinguished career at UPS where he last served as the president of global fleet maintenance and engineering.

“I would like to congratulate Carlton on his appointment as Chairman in such paramount stage for REE as we prepare to begin deliveries and service, ramp up production and accelerate growth,” said Daniel Barel, CEO and co-founder of REE Automotive. “Carlton’s leadership and unique industry perspective, having worked in the global fleet industry for decades, combined with his ability to truly understand why REE’s technology and business model sets us apart. Carlton has already provided great value as a board member since his appointment in early June, and I look forward to continuing working closely with him.”

“I have been around trucks my entire life, and I have a good understanding of what good looks like. REE’s technology is a game changer in the industry,” said Carlton Rose. “The U.S. commercial fleet market is on the cusp of a major transformation due to the move towards electrification. This shift offers benefits that extend beyond carbon neutrality, fundamentally changing how companies build, acquire, manage, and maintain their fleets. In the next few quarters, we expect to see crucial milestones for the company. Our understanding of our customers and our partners will be vital as we build out our fleet relationships, continue to expand our dealer network, and bring winning reliable technology to the market. I have been following REE closely for the past four years and as I have always said, ‘better is before us,’ and REE will be an essential part of achieving better.”

Arik Steinberg will voluntarily step down and not stand for re-election at the AGM. Following these changes, REE’s Board will comprise of eight directors; three of them women and four of whom are independent.

“Arik has been a part of REE for more than six years, and we were fortunate to have had his insight and leadership as Chairman of our Board,” Barel added. “We shared successes and faced challenges and I want to thank Arik for his years of service and support to REE”.

To learn more about REE Automotive’s patented technology and unique value proposition that position the company to break new ground in e-mobility, visit www.ree.auto.

Media Contact

Malory Van Guilder
Skyya PR for REE Automotive
+1 651-335-0585
[email protected]

Investor Contact

Kamal Hamid
VP Investor Relations | REE Automotive
+1 303-670-7756
[email protected]

About REE Automotive

REE Automotive (Nasdaq: REE) is an automotive technology company that allows companies to build any size or shape of electric vehicle on their modular platforms. With complete design freedom, vehicles Powered by REE are equipped with the revolutionary REEcorner^TM, which packs critical vehicle components (steering, braking, suspension, powertrain and control) into a single compact module positioned between the chassis and the wheel. With proprietary by-wire technology for drive, steer and brake control that eliminate the need for mechanic connections, all four identical REEcorners^TM enable REE to build the industry’s flattest EV platforms with more room for passengers, cargo and batteries. REE platforms are future proofed, autonomous capable, offer a low TCO, and drastically reduce the time to market for fleets looking to electrify. To learn more visit www.ree.auto.

Caution About Forward-Looking Statements

This communication includes certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding REE or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to plans, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “aim” “anticipate,” “appear,” “approximate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “would”, “designed,” “target” and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements in this communication may include, among other things, statements about REE’s strategic and business plans, technology, relationships and objectives, including its ability to meet certification requirements, the impact of trends on and interest in our business, or product, intellectual property, REE’s expectation for growth, and its future results, operations and financial performance and condition.

These forward-looking statements are based on REE’s current expectations and assumptions about future events and are based on currently available information as of the date of this communication and current expectations, forecasts, and assumptions. Although REE believes that the expectations reflected in forward-looking statements are reasonable, such statements involve an unknown number of risks, uncertainties, judgments, and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These factors are difficult to predict accurately and may be beyond REE’s control. Forward-looking statements in this communication speak only as of the date made and REE undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur.

Uncertainties and risk factors that could affect REE’s future performance and could cause actual results to differ include, but are not limited to: REE’s ability to commercialize its strategic plan, including its plan to successfully evaluate, obtain regulatory approval, produce and market its P7 lineup; REE’s ability to maintain and advance relationships with current Tier 1 suppliers and strategic partners; development of REE’s advanced prototypes into marketable products; REE’s ability to grow and scale manufacturing capacity through relationships with Tier 1 suppliers; REE’s estimates of unit sales, expenses and profitability and underlying assumptions; REE’s reliance on its UK Engineering Center of Excellence for the design, validation, verification, testing and homologation of its products; REE’s limited operating history; risks associated with building out of REE’s supply chain; risks associated with plans for REE’s initial commercial production; REE’s dependence on potential suppliers, some of which will be single or limited source; development of the market for commercial EVs; risks associated with data security breach, failure of information security systems and privacy concerns; risks related to lack of compliance with Nasdaq’s minimum bid price requirement; future sales of our securities by existing material shareholders or by us could cause the market price for the Class A Ordinary Shares to decline; potential disruption of shipping routes due to accidents, political events, international hostilities and instability, piracy or acts by terrorists; intense competition in the e-mobility space, including with competitors who have significantly more resources; risks related to the fact that REE is incorporated in Israel and governed by Israeli law; REE’s ability to make continued investments in its platform; the impact of the COVID-19 pandemic, interest rate changes, the ongoing conflict between Ukraine and Russia and any other worldwide health epidemics or outbreaks that may arise and adverse global conditions, including macroeconomic and geopolitical uncertainty; the global economic environment, the general market, political and economic conditions in the countries in which we operate; fluctuations in interest rates and foreign exchange rates; the need to attract, train and retain highly-skilled technical workforce; changes in laws and regulations that impact REE; REE’s ability to enforce, protect and maintain intellectual property rights; REE’s ability to retain engineers and other highly qualified employees to further its goals; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in REE’s annual report filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 28, 2023 and in subsequent filings with the SEC.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a2f4cfd9-6a7e-49d9-adfd-40ef827908e2

• FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients between two and five years of age
• Prescription Drug User Fee Act (PDUFA) target goal date set for April 28, 2024

WARREN, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced acceptance by the U.S. Food and Drug Administration (FDA) of the Company’s NDA for Libervant™ (diazepam) Buccal Film in pediatric patients between two and five years of age and the assignment of a PDUFA goal date of April 28, 2024.

Aquestive’s NDA for approval of Libervant™ (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) in patients between two and five years of age has been accepted by the FDA. Diastat® (diazepam) Rectal Gel is the only treatment currently available to this patient population for this indication. The Company received tentative approval for Libervant for the treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) in patients 12 years of age and older in August 2022, but Libervant is currently under an orphan drug block to market access until January 2027.

“The FDA’s acceptance of our most recent filing for Libervant is another step forward in bringing this important treatment option to patients,” said Daniel Barber, Chief Executive Officer of Aquestive. “When it comes to the treatment of seizure clusters in pediatric patients with epilepsy five years of age and under, physicians and caregivers have limited options. We believe Libervant, as an oral alternative to existing device-based products, will be well-received by this patient population, if approved with market access.”

About Libervant

Libervant is a buccally, or inside of the cheek, administered film formulation of diazepam, a benzodiazepine intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern. Aquestive developed Libervant as an alternative to the device-based products currently available for patients with refractory epilepsy, including a rectal gel and nasal spray products. The FDA has granted tentative approval for Libervant for treatment of these epilepsy patients 12 years of age and older, with U.S. market access for Libervant for this age group of patients subject to the expiration of the existing orphan drug market exclusivity of a previously FDA approved drug scheduled to expire in January 2027. The NDA submitted today for Libervant for epilepsy patients between two and five years of age is subject to FDA approval, including for U.S. market access.

About Aquestive

Aquestive is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. For more information, visit Aquestive.com and follow us on LinkedIn.

Forward-Looking Statement

Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the approval and related timing of the NDA for Libervant by the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy between two and five years of age; regarding the approval for U.S. market access of Libervant for these epilepsy patients aged 12 and older, and overcoming the orphan drug market exclusivity of a competing FDA approved nasal spray product extending to January 2027 for this age group of the patient population; regarding the potential benefits Libervant could bring to patients; and other statements that are not historical facts. These forward-looking statements are subject to the uncertain impact of the COVID-19 global pandemic on the Company’s business including with respect to its clinical trials, including site initiation, enrollment and timing and adequacy of clinical trials, on supply chain, manufacture, and distribution; and ongoing availability of an appropriate labor force and skilled professionals to produce our products.

These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks that the FDA will not approve Libervant for epilepsy patients between two and five years of age or grant U.S. market access for Libervant for any age group of the epilepsy patient population, including as covered under the NDA for Libervant submitted for epilepsy patients aged two to five, by overcoming the seven year orphan drug market exclusivity of an FDA approved competing product in effect until January 2027, and there can be no assurance that the Company will be successful in obtaining any such product approval or approval for U.S. market access; risk that a competing pediatric epilepsy product of Libervant will receive FDA approval prior to the Company’s receipt of FDA approval of the Libervant NDA for this pediatric age group of the epilepsy patient population; risk relating to the unpredictability of the FDA’s decisions regarding orphan drug exclusivity; risk of litigation brought by third parties relating to overcoming their orphan drug exclusivity of an FDA approved product should the FDA approve Libervant for U.S. market access for any age group of epilepsy patients; risk in obtaining market access for Libervant for other reasons; risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of the Company’s product development activities; risk of the Company’s failure to generate sufficient data in its NDA submission for FDA approval of Libervant, and there can be no assurance that the Company will be successful in obtaining such approval; risk of the rate and degree of market acceptance of our product candidate Libervant; risk of the success of any competing products; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to the Company’s products; risk of unexpected patent developments; risk of insufficient capital and cash resources, including insufficient access to available debt and equity financing and revenues from operations, to satisfy all of the Company’s short-term and longer term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund future development activities for Libervant; uncertainties related to general economic, political, business, industry, regulatory, financial and market conditions and other unusual items; and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K and the Company’s other filings with the Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.

Investor Inquiries:

ICR Westwicke
Stephanie Carrington
[email protected]
646-277-1282 

HOUSTON, Sept. 11, 2023 (GLOBE NEWSWIRE) — Sysco Houston announced today that Robert Hernandez, Delivery Driver, will represent Sysco at the International Foodservice Distributors Association (IFDA) National Championship in Orlando, Florida, October 12-14, 2023.

Robert emerged as a Top 16 finalist out of 2,200 other Sysco competitors based on his skills performance and safety record during his 23-year tenure at Sysco. As a finalist, Sysco also provides Robert with a prize package that includes a Walt Disney World^® family vacation.

Sysco Rodeo is an annual competition for the company’s industrial athletes to display their knowledge and skills in driving, selecting, and forklift operations. This year’s Rodeo had individual competitions taking place at 92 Sysco sites across the U.S. between May and August.

The top 12 delivery partners and the top four warehouse colleagues will now advance to Orlando, putting their skills to the test against other top industry drivers and warehouse colleagues from across the country.

“All of us at Sysco are so proud of Robert and all our driver and warehouse colleagues who participated in Sysco Rodeo this year,” said Daniel Purefoy, Sysco’s Senior Vice President, Chief Supply Chain Officer. “These events bring fun, food, and friendly competition for the participants and their families while highlighting the skill and talent that makes Sysco the best in the business. We look forward to bringing home some trophies from Orlando!”

About Sysco

Sysco is the global leader in selling, marketing and distributing food products to restaurants, healthcare and educational facilities, lodging establishments and other customers who prepare meals away from home. Its family of products also includes equipment and supplies for the foodservice and hospitality industries. With more than 72,000 colleagues, the company operates 334 distribution facilities worldwide and serves approximately 725,000 customer locations. For fiscal year 2023 that ended July 1, 2023, the company generated sales of more than $76 billion. Information about our Sustainability program, including Sysco’s 2022 Sustainability Report and 2022 Diversity, Equity & Inclusion Report, can be found at www.sysco.com.

Media Contact:

Shannon Mutschler
Sr. Director, External Communications
[email protected]

PALMETTO, Fla., Sept. 11, 2023 (GLOBE NEWSWIRE) — Sysco West Coast Florida announced today that Antonio Garcia, Forklift Operator, will represent Sysco at the International Foodservice Distributors Association (IFDA) National Championship in Orlando, Florida, October 12-14, 2023.

Antonio emerged as a Top 16 finalist out of 2,200 other Sysco competitors based on his skills performance and safety record during his 9-year tenure at Sysco. As a finalist, Sysco also provides Antonio with a prize package that includes a Walt Disney World^® family vacation.

Sysco Rodeo is an annual competition for the company’s industrial athletes to display their knowledge and skills in driving, selecting, and forklift operations. This year’s Rodeo had individual competitions taking place at 92 Sysco sites across the U.S. between May and August.

The top 12 delivery partners and the top four warehouse colleagues will now advance to Orlando, putting their skills to the test against other top industry drivers and warehouse colleagues from across the country.

“All of us at Sysco are so proud of Antonio and all our driver and warehouse colleagues who participated in Sysco Rodeo this year,” said Daniel Purefoy, Sysco’s Senior Vice President, Chief Supply Chain Officer. “These events bring fun, food, and friendly competition for the participants and their families while highlighting the skill and talent that makes Sysco the best in the business. We look forward to bringing home some trophies from Orlando!”

About Sysco

Sysco is the global leader in selling, marketing and distributing food products to restaurants, healthcare and educational facilities, lodging establishments and other customers who prepare meals away from home. Its family of products also includes equipment and supplies for the foodservice and hospitality industries. With more than 72,000 colleagues, the company operates 334 distribution facilities worldwide and serves approximately 725,000 customer locations. For fiscal year 2023 that ended July 1, 2023, the company generated sales of more than $76 billion. Information about our Sustainability program, including Sysco’s 2022 Sustainability Report and 2022 Diversity, Equity & Inclusion Report, can be found at www.sysco.com.

Media Contact:

Shannon Mutschler
Sr. Director, External Communications
[email protected]

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer. Dr. Ryan Phan, who stepped down as the Company’s Chief Scientific and Operating Officer, remains as an advisor through the end of the year to help with the transition and provide scientific and operational advice related to ongoing product development programs.

Dr. Berry is a seasoned scientific leader with over two decades of commercial, government and academic experience. A recognized international expert in immunoassay development, antibody technology, and infectious diseases, he brings a proven track record of innovation and scientific achievement in both small and large companies.

“We warmly welcome Jody to our executive team. Jody is a dynamic leader with decades of experience launching disruptive products and building effective research and development teams,” said Nicole Sandford, Chief Executive Officer of Aspira. “Jody joins us at a key inflection point as we finalize plans to launch an OvaWatch longitudinal monitoring application and our first-of-its-kind EndoCheck test by the end of the year.”

Dr. Berry added, “I am excited to join a team of professionals focused on improving the lives of women through the development of cutting-edge diagnostic tools. I see tremendous market potential for Aspira’s products, and I look forward to leading the R&D team through two exciting launches this year.”

Dr. Jody Berry joins Aspira from OraSure Technologies Inc., where he served as Chief Science Officer responsible for all innovation and product development including the breakthrough discovery of the first integrated swab test for COVID-19. Prior to that, Dr. Berry led immunochemistry research and development for Grifols Diagnostic Solutions, where he was responsible for the design of molecular and tissue culture laboratories and facilities for protein engineering, the development of a companion diagnostic for solid carcinomas using designer novel immune checkpoint inhibitor molecules and immunoassays for blood borne pathogens. He has also served in senior scientific and executive leadership roles for BD Biosciences and Cangene Corporation. Prior to beginning of his prestigious corporate career, he served as Head of Monoclonal Antibody and Bioforensics Response at the National Microbiology Laboratory of the Public Health Agency of Canada. 

Dr. Berry has served as visiting or adjunct professor at Lehigh University, University of Western Michigan, and University of Manitoba. He is the recipient of numerous awards, including the Knudsen Memorial Publication Award from the American Biological Safety Association, the Government of Canada Public Service Commendation Award for post 9/11, CIHR HIV/AIDS Postdoctoral Fellowships, and the Apotex Fermentation Inc. Research Award for Doctoral Research in Molecular Biology. Dr. Berry is author or co-author on over 100 peer-reviewed published journal articles, abstracts, scientific posters, and monographs. Dr. Berry earned his Bachelor of Science with honors from the Department of Microbiology, and his Doctor of Philosophy from the University of Manitoba, Department of Medical Microbiology. His immunobiology studies on Chlamydia trachomatis, the leading cause of pelvic inflammatory disease and involuntary infertility in women, helped to outline protective host responses and to understand type immunity. He completed his post-doctoral fellowship at The Scripps Research Institute, Department of Molecular Biology where he was the first to create immune antibody libraries to HIV from cervical B cells collected from HIV-1 exposed, but uninfected subjects in Kenya. 

About Aspira Women’s Health Inc.

Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite^SM which includes OvaWatch^SM, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus^® combines our FDA-cleared products, Ova1^® and Overa^®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.

EndoCheck^SM, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.

Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the potential effects of widespread use of OvaWatch and the availability of OvaWatch in New York. Forward-looking statements involve a number of risks and uncertainties. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties, and assumptions, including those described in the section entitled “Risk Factors” in Aspira’s Annual Report on Form 10-K for the year ended December 31, 2022, and as supplemented in Aspira’s 10-Q filings for the quarter ended March 31, 2023 and June 30, 2023. These risks include, but are not limited to: our ability to continue as a going concern; our ability to comply with Nasdaq’s continued listing requirements; impacts resulting from potential changes to coverage of Ova1 through our Medicare Administrative Carrier for Ova1; impacts resulting from or relating to the COVID-19 pandemic and actions taken to contain it; anticipated use of capital and its effects; our ability to increase the volume of our product sales; failures by third-party payers to reimburse for our products and services or changes to reimbursement rates; our ability to continue developing existing technologies and to develop, protect and promote our proprietary technologies; plans to develop and perform laboratory developed tests; our ability to comply with Food and Drug Administration (“FDA”) regulations that relate to our products and to obtain any FDA clearance or approval required to develop and commercialize medical devices; our ability to develop and commercialize additional diagnostic products and achieve market acceptance with respect to these products; our ability to compete successfully; our ability to obtain any regulatory approval required for our future diagnostic products; or our suppliers’ ability to comply with FDA requirements for production, marketing and post-market monitoring of our products; our ability to maintain sufficient or acceptable supplies of immunoassay kits from our suppliers; in the event that we succeed in commercializing our products outside the United States, the political, economic and other conditions affecting other countries; changes in healthcare policy; our ability to comply with the additional laws and regulations that apply to us in connection with the operation of Aspira Labs; our ability to use our net operating loss carryforwards; our ability to use intellectual property; our ability to successfully defend our proprietary technology against third parties; our ability to obtain licenses in the event a third party successfully asserts proprietary rights; the liquidity and trading volume of our common stock; the concentration of ownership of our common stock; our ability to retain key employees; our ability to secure additional capital on acceptable terms to execute our business plan; business interruptions; the effectiveness and availability of our information systems; our ability to integrate and achieve anticipated results from any acquisitions or strategic alliances; future litigation against us, including infringement of intellectual property and product liability exposure; and additional costs that may be required to make further improvements to our laboratory operations. The events and circumstances reflected in Aspira’s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Aspira expressly disclaims any obligation to update, amend or clarify any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:


Monique Kosse 
Managing Director
LifeSci Advisors, LLC
Tel: 212-915-3820
[email protected]

NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2022. The Wainwright Conference – which takes place at the Lotte New York Palace Hotel in New York City, New York – brings together thought leaders and practitioners from numerous fields to participate in presentations, one-on-one investor meetings, and networking opportunities with other attendees.

Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation on Wednesday, September 13, 2023 at 12:00 PM ET.

A live webcast of the discussion will be available at this link as well as through the investor relations section of the Company’s website at www.galectintherapeutics.com.

About Belapectin

Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH when it has progressed to the liver cirrhosis stage as well as advanced cancers. Galectin-3 is produced by activated macrophages, a key inflammatory cell, and plays a major role in diseases that involve scarring of organs, including fibrotic disorders of the liver, lung, kidney, heart, as well as in the cancerous tumor microenvironment. Belapectin binds to galectin-3 and disrupts its function. Belapectin, because of its unique structure, is also captured by activated macrophages and exerts its activity directly at the source of galectin-3 production. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis associated with liver cirrhosis, a disease that is characterized by an invasion of activated macrophages into the liver parenchyma. A Phase 2 study showed belapectin may prevent the development of esophageal varices in NASH cirrhosis, and these results provide the basis for the conduct of the NAVIGATE trial. The NAVIGATE trial (www.NAVIGATEnash.com), titled “A Seamless Adaptive Phase 2b/3, Double-Blind, Randomized, Placebo-controlled Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis,” completed randomization of 357 patients in February 2023 with top-line data expected from the Phase 2b portion in the fourth quarter of 2024, and is posted on www.clinicaltrials.gov (NCT04365868). Galectin-3 has a significant role in cancer, in making the tumor microenvironment resistant to immunological treatment, and the Company has supported a Phase 1b study in combined immunotherapy of belapectin and Keytruda in advanced melanoma and in head and neck cancers. This trial provided a strong rationale for moving forward into a Company-sponsored Phase 2 development program, which the company is exploring.

About Fatty Liver Disease with Advanced Fibrosis and Cirrhosis

Non-alcoholic steatohepatitis (NASH), a complication of fatty liver disease, has become a common disease of the liver with the rise in obesity and other metabolic diseases. NASH is estimated to affect up to 28 million people in the U.S. It is characterized by the presence of excess fat in the liver along with inflammation and hepatocyte damage in people who consume little or no alcohol. Over time, patients with NASH can develop excessive fibrosis, or scarring of the liver, and ultimately liver cirrhosis. It is estimated that as many as 1 to 2 million individuals in the U.S. will develop cirrhosis as a result of NASH, for which liver transplantation is the only curative treatment available. Approximately 9,000 liver transplants are performed annually in the U.S. There are no drug therapies approved for the treatment of liver fibrosis or cirrhosis.

About Galectin Therapeutics

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Company Contact:

Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor GR-MD-02.

EMERYVILLE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — NMI Holdings, Inc., (Nasdaq:NMIH), the parent company of National Mortgage Insurance Corporation (National MI), today announced that Lesley Alli and Andrew Greenberg have joined the company as Senior Vice Presidents and members of its Executive Committee.

Lesley Alli has been named Senior Vice President, Industry Relations and Corporate Communications. In this role, Ms. Alli will be responsible for leading the company’s efforts in external public and industry relations, including corporate communications, public policy, and government enterprise and agency affairs. She has more than 20 years of experience in the mortgage industry and most recently served as the Chief Investor and Industry Relations Officer of Home Point Financial Corporation. Ms. Alli was named to the 2023 list of “Elite Women in Mortgage” by Mortgage Professional America and was recognized as one of Housing Wire magazine’s Top 50 “Women of Influence” in 2021. She previously held senior management roles at Federal National Mortgage Association (Fannie Mae) and Countrywide Home Loans, and holds a bachelor’s degree with distinction from the University of Michigan.

Andrew Greenberg has been named Senior Vice President, Finance. In this new role, Mr. Greenberg will lead the company’s efforts in investor relations, financial planning and analysis, data analytics and treasury. He has more than 25 years of experience in corporate finance and most recently served as Senior Vice President, Business Development and Investor Relations for Triton International Limited, a leading publicly-traded specialty finance company. Before joining Triton, Mr. Greenberg was a Director of investment banking with Barclays where he led strategic advisory and capital raising efforts for financial institution clients. He holds an MBA from Columbia Business School and a bachelor’s degree in mechanical engineering, summa cum laude, from Tufts University. Mr. Greenberg also holds a master’s degree in accounting from Iona College and is a licensed certified public accountant. 

Adam Pollitzer, President and Chief Executive Officer of National MI, said, “We’re delighted to have two executives as talented and experienced as Lesley and Andrew join our strong executive management team. Both bring unique skills and track records of leadership success, and will help National MI continue to lead with impact and drive value for borrowers, lenders and our shareholders.”

About NMI Holdings

NMI Holdings, Inc. (NASDAQ: NMIH) is the parent company of National Mortgage Insurance Corporation (National MI), a U.S.-based, private mortgage insurance company enabling low-down-payment borrowers to realize home ownership while protecting lenders and investors against losses related to a borrower’s default. To learn more, please visit www.nationalmi.com.

Investor Contact

John M. Swenson
Vice President, Investor Relations and Treasury
[email protected]
(510) 788-8417

 

CALERA, Ala., Sept. 11, 2023 (GLOBE NEWSWIRE) — Sysco Central Alabama announced today that William Self, Driver, will represent Sysco at the International Foodservice Distributors Association (IFDA) National Championship in Orlando, Florida, October 12-14, 2023.

William emerged as a Top 16 finalist out of 2,200 other Sysco competitors based on his skills performance and safety record during his 29-year tenure at Sysco. As a finalist, Sysco also provides William with a prize package that includes a Walt Disney World^® family vacation.

Sysco Rodeo is an annual competition for the company’s industrial athletes to display their knowledge and skills in driving, selecting, and forklift operations. This year’s Rodeo had individual competitions taking place at 92 Sysco sites across the U.S. between May and August.

The top 12 delivery partners and the top four warehouse colleagues will now advance to Orlando, putting their skills to the test against other top industry drivers and warehouse colleagues from across the country.

“All of us at Sysco are so proud of William and all our driver and warehouse colleagues who participated in Sysco Rodeo this year,” said Daniel Purefoy, Sysco’s Senior Vice President, Chief Supply Chain Officer. “These events bring fun, food, and friendly competition for the participants and their families while highlighting the skill and talent that makes Sysco the best in the business. We look forward to bringing home some trophies from Orlando!”

About Sysco

Sysco is the global leader in selling, marketing and distributing food products to restaurants, healthcare and educational facilities, lodging establishments and other customers who prepare meals away from home. Its family of products also includes equipment and supplies for the foodservice and hospitality industries. With more than 72,000 colleagues, the company operates 334 distribution facilities worldwide and serves approximately 725,000 customer locations. For fiscal year 2023 that ended July 1, 2023, the company generated sales of more than $76 billion. Information about our Sustainability program, including Sysco’s 2022 Sustainability Report and 2022 Diversity, Equity & Inclusion Report, can be found at www.sysco.com.

Media Contact:

Shannon Mutschler
Sr. Director, External Communications
[email protected]

LONDON, Sept. 11, 2023 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, and Exclusive Networks North America, a global trusted cybersecurity specialist for digital infrastructure, today announced a distribution agreement for Arqit’s unique Symmetric Key Agreement Platform.

Joining Exclusive Networks’ portfolio of industry-leading vendors, channel partners can offer Arqit’s groundbreaking technology that protects against both current and future cyber threats including the risk from quantum computing.

Organizations face a clear and present danger from cyber adversaries employing “store-now, decrypt-later” attacks, stockpiling encrypted data to crack it open with the advent of quantum computing. Arqit’s Symmetric Key Agreement Platform enables end-customers to simplify and strengthen their encryption and move from a complex public-key infrastructure and the need to trust third parties, to a platform designed for the cloud and a world of connected devices.

David Williams, Arqit Founder, Chairman and CEO said:

“We are thrilled to partner with Exclusive Networks North America, making our unique Symmetric Key Agreement Platform available to their industry-leading partners. To counter the growing threats from cyber adversaries in an ever-connected world, organizations need to take urgent action to simplify and strengthen their encryption, safeguarding their data and removing the quantum threat from their risk registers.”

Brian Vincik, Senior Vice President, Exclusive Networks North America said:

“As organizations drive their digital transformation, they need confidence in the cybersecurity solutions available on the market. As a leader in quantum-safe encryption, Arqit’s products and services protect against today’s cyber threats and provide a defence against tomorrow’s quantum attacks. Exclusive Networks is delighted to offer its US partners Arqit’s groundbreaking technology within our trusted, high performance technology ecosystem.”

Notes to Editors

“Store-now, decrypt-later” is a known threat and concerning for data with a long-time value: 

• US Congress: “The rapid progress of quantum computing suggests the potential for adversaries of the United States to steal sensitive encrypted data today using classical computers and wait until sufficiently powerful quantum systems are available to decrypt it” (Congress, Quantum Computing Cybersecurity Preparedness Act, 21 December 2022, link). 

Symmetric cryptography is a solution that can be implemented right now and can be used for both encryption and key exchange: 

• US National Security Agency (NSA): “NSA considers the use of pre-shared symmetric keys in a standards-compliant fashion to be a better near-term post-quantum solution than implementation of experimental postquantum asymmetric algorithms” (NSA, Quantum Computing and Post-Quantum Cryptography, 4 August 2021, link).

The US Government has already directed their agencies to implement symmetric-key protections for National Security Systems (NSS): 

• The White House: “By December 31, 2023, agencies maintaining NSS shall implement symmetric-key protections (e.g., High Assurance Internet Protocol Encryptor (HAIPE) exclusion keys or VPN symmetric key solutions) to provide additional protection for quantum-vulnerable key exchanges” (The White House, National Security Memorandum on Promoting United States Leadership in Quantum Computing While Mitigating Risks to Vulnerable Cryptographic Systems, 4 May 2022, link).

About Arqit

Arqit supplies a unique Symmetric Key Agreement Platform-as-a-Service which makes the communications links of any networked device, cloud machine or data at rest secure against both current and future forms of attack on encryption – even from a quantum computer. Arqit’s Symmetric Key Agreement Platform delivers a lightweight software agent that allows devices to create encryption keys locally in partnership with any number of other devices. The keys are computationally secure and operate over zero trust networks. It can create limitless volumes of keys with any group size and refresh rate and can regulate the secure entrance and exit of a device in a group. The agent is lightweight and will thus run on the smallest of end point devices. The Product sits within a growing portfolio of granted patents but also works in a standards compliant manner which does not oblige customers to make a disruptive rip and replace of their technology. Arqit was recently awarded the Innovation in Cyber award at the UK National Cyber Awards and Cyber Security Software Company of the Year Award at the UK Cyber Security Awards. www.arqit.uk

About Exclusive Networks

Exclusive Networks (EXN) is a global cybersecurity specialist that provides partners and end-customers with a wide range of services and product portfolios via proven routes to market. With offices in over 45 countries and the ability to serve customers in over 170 countries, we combine a local perspective with the scale and delivery of a single global organization.

Our best-in-class vendor portfolio is carefully curated with all leading industry players. Our services range from managed security to specialist technical accreditation and training and capitalize on rapidly evolving technologies and changing business models. For more information visit www.exclusive-networks.com

Media relations enquiries:

Arqit: [email protected]
Gateway: [email protected]

Investor relations enquiries:

Arqit: [email protected]
Gateway: [email protected]

Caution About Forward-Looking Statements
This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements are based on Arqit’s expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Arqit’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Arqit to predict these events or how they may affect it. Except as required by law, Arqit does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date this communication is issued. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur. Uncertainties and risk factors that could affect Arqit’s future performance and cause results to differ from the forward-looking statements in this release include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against the Arqit related to the business combination, (ii) the ability to maintain the listing of Arqit’s securities on a national securities exchange, (iii) changes in the competitive and regulated industries in which Arqit operates, variations in operating performance across competitors and changes in laws and regulations affecting Arqit’s business, (iv) the ability to implement business plans, forecasts, and other expectations, and identify and realise additional opportunities, (v) the potential inability of Arqit to convert its pipeline into contracts or orders in backlog into revenue, (vi) the potential inability of Arqit to successfully deliver its operational technology, (vii) the risk of interruption or failure of Arqit’s information technology and communications system, (viii) the enforceability of Arqit’s intellectual property, and (ix) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Arqit’s annual report on Form 20-F (the “Form 20-F”), filed with the U.S. Securities and Exchange Commission (the “SEC”) on 14 December 2022 and in subsequent filings with the SEC. While the list of factors discussed above and in the Form 20-F and other SEC filings are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realisation of forward-looking statements.